Despite the recognized importance of chronic kidney disease (CKD), the United States currently lacks a comprehensive, systematic surveillance program that captures and tracks all aspects of CKD in the population. As part of its CKD Initiative, the Centers for Disease Control and Prevention (CDC) funded two teams to jointly initiate the development of a CKD surveillance system. Here, we describe the process and methods used to establish this national CDC CKD Surveillance System. The major CKD components covered include burden (incidence and prevalence), risk factors, awareness, health consequences, processes and quality of care, and health system capacity issues. Goals include regular reporting of the data collected, plus development of a dynamic project web site and periodic issuance of a CKD fact sheet. We anticipate that this system will provide an important foundation for widespread efforts toward primary prevention, earlier detection, and implementation of optimal disease management strategies, with resultant increased awareness of CKD, decreased rates of CKD progression, lowered mortality, and reduced resource utilization. Final success will be measured by usage, impact, and endorsement.
C hronic kidney disease (CKD) has been recognized as a public health priority since the late 1980s (1, 2) . A dedicated, comprehensive, and systematic surveillance program that captures and tracks all aspects of CKD in those not yet receiving renal replacement therapy is fundamentally important for the ongoing assessment of the national CKD burden. Dissemination of its findings would raise awareness about this disease and its impact on the population and health care system, and would provide the impetus for public health action.
According to the most recent estimates from the National Health and Nutrition Examination Survey (NHANES), 13% of the US adult population has CKD (3). Kidney disease is listed as the ninth most common cause of death by the National Center for Health Statistics (4) . However, most patients are unaware of their declining kidney function until it is in its late stages (5,6), or they succumb prematurely, typically to cardiovascular disease (7, 8) . Progression of CKD, and its attendant comorbidity, can be slowed or potentially even halted with optimal medical care (9 -11), with implications for increased lifespan, quality of life, and lower societal cost. Therefore, it is critical to identify those at risk or in the early stages of the disease, with the intent of effective implementation of proven preventive and therapeutic strategies.
Following a legislative mandate from the US Congress (12), the Division of Diabetes and Translation at the Centers for Disease Control and Prevention (CDC) funded two teams at the University of Michigan and Johns Hopkins University to jointly initiate the development of a CKD surveillance system in the United States.
This article describes the process and methods used toward establishing a national CDC CKD Surveillance System, followed by a discussion about key aspects, including successes and challenges faced during the early phases of its development.
Foundational Work

Definition of Surveillance and Attributes of an Ideal Surveillance System
Disease surveillance has been defined by the CDC as "ongoing, systematic, collection, analysis and interpretation of health data essential to the planning, implementation and evaluation of public health practice, closely integrated with the timely dissemination of these data to those who need to know" (13) .
Surveillance can be "active" or "passive." Active surveillance typically involves interaction with providers to identify cases of disease, often by visiting health care facilities and reviewing medical records, as well as interviewing health professionals, patients, and/or persons in the community. Passive surveillance typically involves using existent data, which can be mandated for collection or assembled for other reasons (14) . Although active surveillance is typically more accurate and less bias-prone, it typically requires more resources and can involve privacy and confidentiality issues. Thus, most chronic disease surveillance systems, particularly on a national level, use a passive approach.
The attributes of an ideal chronic disease surveillance system, in general, have been characterized as (15) : (1) simplicity of system structure and operation; (2) flexibility to look at new questions posed by researchers and to adapt to changes in technology and reporting definitions; (3) high data quality; (4) acceptability, or enthusiasm and willingness on the part of stakeholders and data sources to participate in the system; (5) a high degree of sensitivity for capturing all events and monitoring trends; (6) a high positive predictive value for capturing true cases; (7) representativeness of information pertaining to the general US population; (8) timeliness in the processing and delivery of information necessary to implement health care changes; and (9) stability of the system to reliably operate and provide information when users call upon it.
Specific Aims
Two multidisciplinary teams based at the University of Michigan and Johns Hopkins University were selected to collaboratively design and implement a national CKD surveillance system with the CDC. Teams consisted of epidemiologists, generalist and specialist clinicians, biostatisticians and others. The specific aims for the development of the CDC CKD Surveillance System project, as conceived by the CDC and the teams, appear in Table 1 .
Establishment of a Structure and Process
To facilitate collaboration within the project, a steering committee, including all academic and CDC members and guided by the teams' Principal Investigators and the CDC Technical Advisor, was formed. It was envisaged that members would meet monthly to share information, discuss options, gather input, and make decisions. In addition, both Principal Investigators and their respective team members would meet on a weekly basis by teleconference. After the steering committee's establishment, the two teams drafted a common protocol, on the basis of the ideas of both teams and the CDC. This protocol was iteratively developed and described the collaborative process whereby the teams would create a pilot CKD surveillance system. Final approval for the common protocol was sought from the project's steering committee.
An external advisory group consisting of members from key stakeholder organizations, including government agencies, professional societies, advocacy groups, and other national experts, was formed (see Acknowledgments). The envisioned role of the Advisory Group was to provide stakeholder input on various issues, including the importance of individual topics and measures and the evaluation of data sources (see below).
Enumeration of Topics and Priority Measures Relevant to CKD Surveillance
With the organizational and structural tasks completed, the teams moved forward to identify relevant topics (broad areas important to capture in a surveillance system) and measures (more specific concepts within the topics) that a CKD surveillance system should encompass. Six topics to be addressed were identified: (1) burden of CKD (prevalence/ incidence), (2) awareness of CKD, (3) risk factors for CKD, (4) health consequences in CKD, (5) processes and quality of care in CKD, and (6) health system capacity for CKD. Within Table 1 . Initial specific aims of the CDC CKD Surveillance System Project a Aim 1.
Enumerate topics relevant to CKD surveillance and identify measures within each topic 2.
Identify existing national and regional data sources that contain possible topics, measures, and indicators for CKD surveillance 3.
Evaluate each data source/topic-measure-indicator combination using available scientific evidence and achieve consensus as to which data sources should be part of a CKD surveillance system 4.
Develop a comprehensive plan for integration of all the data source/topic-measureindicator combinations into a functional national surveillance system 5.
Assess the feasibility of integration of all the data sources into a functional national surveillance system 6.
Conduct a pilot test of the system 7.
Produce interim reports of CKD surveillance with recommendations toward the implementation of a national CKD surveillance system these topics, a comprehensive list of 136 possible measures was generated by using a modified two-step Delphi process, typically used to gain consensus on a particular subject (16) . The first step involved the enumeration of possible measures under each major topic on the basis of a literature review and the opinion of experts comprising both the steering committee and advisory group. As a next step, the steering committee and advisory group members were enlisted to rate each of the possible measures for their importance and relevance to a CKD surveillance system. Measures were ranked in importance from 1 (least important) to 5 (extremely important). Ratings from advisory group and steering committee members were standardized by multiplying by the ratio (overall group average for all measures)/(individual's average for all measures). Standardized ratings were then averaged for each measure. The top five measures from each topic area were chosen for exploration during the first phase of the surveillance system, with the additional measures reserved for future exploration. Table 2 displays the six broad topics and the top five measures within each of the topics. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate.
a Of a possible maximum rating of 5 (extremely important). Tied ranks are represented, giving each measure the smallest rank possible.
The complete list of all 136 measures and their rankings is provided in the Supplemental Information.
Identification and Feasibility Assessment of Data Sources
In designing this CKD surveillance system, the teams considered both pre-existing and ongoing prospective data collection efforts, datasets rich in CKD-related information, and datasets procurable from the various components of the US health care system. The latter have the potential to continually provide data pertaining to CKD surveillance from large segments of the population. This approach was deemed more efficient and less costly or resource-intensive than "active" surveillance. For the surveillance system to be nationally representative, care was taken to identify data sources that covered all segments of the population (e.g., children, young adults, the elderly, ethnic or racial minorities, the uninsured, etc.; see Figure 1 ) and could yield information on the entire spectrum of CKD, from minor impairment (stage 1) to dialysis (stage 5D) or transplantation (stage 5T), but focusing primarily on CKD before the onset of end-stage renal disease (ESRD).
Similar to the process used in the enumeration of potential measures, a modified Delphi process was invoked for the enumeration, evaluation, and subsequent prioritization of possible data sources for the surveillance system. A comprehensive list of potential data sources was first developed on the basis of Internet and literature searches and consensus within the steering committee (see Table 3 for a sample). These included national surveys, registries, population-based and prospective cohort studies, private laboratories, and health care system data. A standardized questionnaire was used to interview contacts knowledgeable about each data source to: (1) gather information about available data for the prioritized topics and measures; and (2) evaluate a data source's potential attributes, such as availability for participation in the surveillance system, data quality, representativeness, defined denominator, timeliness (time between data collection and completed processing for disbursal), sensitivity, stability, simplicity (time and personnel necessary for the data source to transfer data to us), and flexibility (whether the data source had the ability to add or change variables with the advent of new technology or guidelines).
Evaluation and Selection of Data Sources
The teams compiled and summarized the data source information, then enlisted both the steering committee and the advisory group to (1) rank the top data sources for each measure (using the top 10 measures within each broad topic), and also (2) rank the best data sources overall. These rankings allowed prioritization of the data sources for the pilot phase of the CDC CKD Surveillance System. Table 4 is a display of the top three data sources, as ranked by the steering committee and advisory group, for each of the top five measures within each topic.
Before data analysis, the teams identified possible gaps or deficiencies in the data sources, which allowed assessment of the need for exploration of other/new data sources in the future. It should be emphasized, however, that only real-time and ongoing procurement and analysis of data from these sources will enable the investigators to provide a definitive evaluation of data deficiencies.
Health care system data initially considered for inclusion in the CDC CKD Surveillance System included: (1) the Veterans' Affairs Health System (national) data, (2) data from a regional combination of managed care plans from southeastern lower Michigan, (3) 
Integration of the Data Sources and Pilot Testing of the System
We have assembled databases from a variety of the topranked data sources. These databases continue to be used to evaluate the top-ranked measures, using appropriate numerators and denominators. Quality control measures were performed to check data completeness and identify possible errors; where possible, questions were directed back to the source for resolution. In addition to primary data analysis of pre-existing data, previously published data germane to CKD surveillance were incorporated, with due permission from authors and publishers. The pilot testing of the surveillance system methodology has thus far resulted in the production of a report (see below) detailing the results of the analyses of each measure from the multiple data sources.
Continuing and Future Work
Dissemination of Findings
Regular submission of reports will be an integral part of this project. In the very near future, these reports will be made publicly available on the CDC web site. An interim report of the pilot and feasibility phase of the CDC CKD Surveillance System A CDC CKD Surveillance web site is currently under development in collaboration with the CDC, and it is considered an important task in the current phase of this project. The information contained on the CDC web site will provide feedback to the medical and research communities at regular intervals by the detailed interactive display of CKD-related data and trends in the United States. The CDC CKD Surveillance web site will also support the intergovernmental agency development of a CKD fact sheet. The fact sheet is intended to be a summary of salient information pertaining to CKD, intended primarily for health care professionals, policymakers, the media, and the public. The CDC is leading the development of the fact sheet and plans to release it at regular intervals.
Project Significance, Successes, and Challenges
The primary project goal remains the establishment of a dedicated, comprehensive, and ongoing prospective surveillance system for CKD for the United States, focusing initially on data from a variety of currently existing data sources that either singly or in combination represent the US population. Dissemination of the findings is intended to increase awareness of CKD and its importance as a major public health problem and stimulate multiple stakeholders to develop a comprehensive action plan for health improvement. Data on incidence, prevalence, and risk factors collected by the CDC CKD Surveillance System may prompt researchers and health care providers to screen those at risk for CKD and to actively seek out those already affected by, but unaware of, the disease. Providers may find this information useful to evaluate the risk profile of patient populations, as well as risk stratify their patient populations to make appropriate recommendations for targeted primary and secondary prevention. Analysis of health care data may assist researchers and clinicians in identifying optimal practice patterns to guide practice as well as generate new hypotheses, kindling new research. Laboratory and pharmacy data from health care systems may allow observation of diagnostic and therapeutic practice patterns in both those with risk factors and those already diagnosed with CKD. Together, these elements would allow comprehensive tracking of all aspects of CKD, including current health care usage and predicting implications for the future.
During the pilot and implementation stages of the project, major achievements included the establishment of a common protocol for national CKD surveillance, the installation of a multidisciplinary steering committee and advisory group, development and prioritization of key topics and multiple potential measures related to CKD, the evaluation and prioritization of multiple data sources, data analyses, and the successful development and submission of the initial report of the surveillance system to the CDC.
Major challenges to the project have included the identification and acquisition of datasets that allow the long-term monitoring of CKD and its care in the United States. Team members are continuing to test future data procurement from currently participating data sources while exploring strategies for successful integration of data from the disparate sources; e.g., by testing the feasibility of calculating US population-based estimates from individual data sources and/or by attempting to create a combined database derived from disparate health care system data sources.
Team members are also continually assessing new data sources for inclusion in the system. The system seeks to be sensitive and flexible to new advances in the field and adaptive to developing newer evidence-based strategies for surveillance. New evidence-based measures will be considered for inclusion on the basis of recent advances in CKD, such as changes in definitions, laboratory technology, pharmacology, clinical practice guidelines, or the identification of novel risk factors or methods of estimating/measuring kidney function. As a final challenge, the seamless integration of the CDC CKD Surveillance System with other chronic disease surveillance systems remains a high priority. A number of organizations, both national and regional, are committed to the task of addressing the problem of CKD in the United States. Examples include the US Renal Data System, the National Kidney Foundation, the National Kidney Disease Education Program, the National Diabetes Surveillance System, and the Centers for Medicare and Medicaid Services. Interagency agreements between several national organizations currently exist, and regular interaction between the key stakeholders is critical not only for developing consensus guidelines but also implementing public health action to decrease CKD burden in the United States.
Summary and Conclusions
In summary, we have described efforts to create a national CKD surveillance system. Six broad topics and several measures were identified and prioritized for CKD surveillance. A pilot and feasibility phase of obtaining, analyzing, and synthesizing data obtained from a variety of data sources is currently ongoing, along with preparations for the development and regular production of an annual report of the CDC CKD Surveillance System, a CKD fact sheet for widespread dissemination, and a regularly updated and interactive project web site. It is envisioned that this dedicated national CKD Surveillance System will be a readily available and useful resource for health care providers, public health authorities, and policy makers alike. In the future, greater use of active surveillance methodologies complementing the current approach may be considered. Advances in health information technology are very likely to have a major impact on the surveillance system of the future. We believe that this CDC CKD Surveillance System will be vital for an ongoing assessment of the national CKD burden and its impact on the population at large as well as the health care system. We hope that it will lay the foundation for widespread efforts toward primary prevention, earlier detection, and implementation of optimal disease management strategies, with resultant decreased rates of CKD progression and lowered morbidity and mortality. 
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